Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The standard approach to controlling pain after mastectomy includes intravenous and oral pain-relieving medications. In this study, researchers are determining if adding a long-acting local anesthetic, bupivacaine, into the wound at the end of the operation is more effective at reducing pain than the standard medications alone for women having a mastectomy on one side with no immediate reconstruction afterward.
Researchers are assessing a lower dose of standard radiation therapy after chemotherapy in young people with germinomas. The patients in this study have germinomas of the central nervous system (brain or spinal cord). It is hoped that this new approach can destroy germinomas with fewer long-term side effects.
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
The purpose of this study is to find the highest dose of the investigational treatment UCART22 that can be given safely in children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has come back or continued to grow despite treatment. UCART22 is a form of CAR T-cell therapy. It is made from white blood cells (T cells) from healthy donors. The T cells are genetically modified in a laboratory to identify and destroy cancer cells containing a protein called CD22.
Researchers are assessing the iberdomide with belantamab mafodotin and dexamethasone in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even with treatment.
The purpose of this study is to find out how cancer treatments (chemotherapy and/or radiation therapy) affect reproductive and sexual health in people with early-onset colorectal cancer (diagnosed before age 50). Researchers will observe and track changes in hormone levels and in sexual and reproductive health in the study participants. This information will help them learn more about how cancer treatments affect reproductive and sexual health, including the ability to have children (fertility).
Cetuximab binds to a protein called EGFR, which is found on some types of tumor cells. This drug may help keep tumor cells from growing. Pembrolizumab helps the body's immune system attack the tumor and may interfere with tumor growth and spread.
A standard approach for early-stage rectal cancer is treatment with chemotherapy and radiation therapy followed by surgery. In this study, researchers are comparing two approaches to prevent the need for rectal resection (removal of all or nearly all of the rectum) in people with early rectal cancer: chemotherapy or chemotherapy and radiation with observation or limited surgery (removing only the area with the tumor, not the entire rectum).
Researchers are assessing the use of cobimetinib to treat Langerhans cell histiocytosis (LCH) and other histiocytic disorders. Histiocytic disorders are diseases caused by the abnormal function or buildup of immune cells called histiocytes. Cobimetinib works by blocking the activity of a protein called MEK. This protein leads to the abnormal growth and development of histiocytosis cells.
Cancer and its treatment may affect sexual and reproductive health. The purpose of this study is to evaluate sexual and reproductive health over several years among women age 50 and younger newly diagnosed with breast cancer or lymphoma.
